about
Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsThe use of mass spectrometry for the analysis of histone modifications.A combination of different mass spectroscopic techniques for the analysis of dynamic changes of histone modifications.A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.Developability assessment during the selection of novel therapeutic antibodies.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.SPR-based assays enable the full functional analysis of bispecific molecules.Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames.Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.Defining the mycoplasma 'cytoskeleton': the protein composition of the Triton X-100 insoluble fraction of the bacterium Mycoplasma pneumoniae determined by 2-D gel electrophoresis and mass spectrometry.Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.Reconstitution of gamma-secretase activity.Development and validation of a novel SPR-based assay principle for bispecific moleculesDuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicityVariable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assemblyEngineering therapeutic bispecific antibodies using CrossMab technology
P50
Q28539968-EE66AC37-3051-4000-ABBE-6BB3AD753F18Q33198543-AACE05E4-2A01-44AA-BCED-F0198270EA4BQ33203615-7D7558AD-B3D2-4C40-854E-C6F5835F0851Q33996024-F6F5BFBA-0B9B-4D89-BBBE-399BDABEB38CQ36164238-8CA12239-7CCD-4B3E-AE07-1FFF4900711AQ37138981-DAF21552-6369-406D-9450-9B0C6E3EBC7EQ38038410-C9951F83-E1A4-4368-94FC-F3DB9544DA70Q38395381-8D45865D-D1BB-494F-B673-F5BB59E6CCB1Q38861238-91F52249-A511-49F1-A877-AA93F8CD7D41Q39307998-4306581D-9EB7-416D-B7F9-D6A23B734B58Q39584161-FC9F681B-0A4E-49AE-9E9F-B2A9B4211AF1Q40980275-8AFABD97-2874-4993-81FE-663286EEAF15Q41864920-9F34C709-B7FE-4D77-9868-A2EEB3BEFA24Q43562837-510E6EB8-13BE-4EAC-A720-B05CDA40BF9EQ43792679-DA5FF7A7-FCAE-4D7A-B7A9-62EA846E1DA1Q44393107-9128D165-0EDB-481F-A70E-699287A79505Q85669402-5D651F15-1928-4700-A255-02983A1627D2Q90127723-B6AF5CFF-A5A3-49DD-9535-F3F252172276Q91250131-8E62D999-62A8-45A2-A0F5-AED401427246Q93213188-553B887B-B6E5-436E-8D26-7884E09F503B
P50
description
researcher ORCID ID = 0000-0002-7343-1077
@en
wetenschapper
@nl
name
Joerg T Regula
@ast
Joerg T Regula
@en
Joerg T Regula
@nl
type
label
Joerg T Regula
@ast
Joerg T Regula
@en
Joerg T Regula
@nl
prefLabel
Joerg T Regula
@ast
Joerg T Regula
@en
Joerg T Regula
@nl
P106
P31
P496
0000-0002-7343-1077